Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 4/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3352661 | 0.88 | PDPK1 (0.43) | PDPK1BRD4HTR6MET | |
| SCHEMBL3354967 | 0.87 | PDPK1 (0.40) | PDPK1BRD4HTR6METCYP11B1 | |
| SCHEMBL3355608 | 0.85 | PDPK1 (0.42) | PDPK1BRD4GRM2HTR6MET | |
| SCHEMBL2750994 | 0.85 | PDPK1 (0.54) | PDPK1BRD4HTR6METALK | |
| SCHEMBL3348264 | 0.85 | BRD4 (0.44) | PDPK1BRD4HTR6MET | |
| SCHEMBL2752683 | 0.84 | PDPK1 (0.47) | PDPK1BRD4GRM2HTR6 | |
| SCHEMBL8192188 | 0.84 | PDPK1 (0.47) | PDPK1BRD4GRM2HTR6 | |
| SCHEMBL13505060 | 0.82 | HTR6 (0.46) | PDPK1BRD4HTR6 | |
| SCHEMBL3348046 | 0.82 | PDPK1 (0.43) | PDPK1BRD4GRM2HTR6 | |
| SCHEMBL8443783 | 0.82 | BCL2L1 (0.41) | BRD4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1749829-B1 | JNK inhibitors | EISAI R&D MAN CO LTD (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1749829-A1 | JNK inhibitors | Eisai London Research Laboratories Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | NFKBIA, CHUK, MAP3K1 | PDPK1 166/4885BRD4 1290/4885GRM2 1225/4885 |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | NFKBIA, CHUK, MAP3K1 | PDPK1 166/4885BRD4 1290/4885GRM2 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.